Our Stocks to Watch today BigString Corporation (OTCBB: BSGC), Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), EPIX Pharmaceuticals (NASD: EPIX), GreenShift Corporation (OTCBB: GSHF), Prime Restaurants, Inc. (OTC: PRSU), Firesky Media Corp. (OTC: FSKM)
Visit http://www.otcpicks.com/ to register for our Daily Market Mover’s Digest Newsletter, and Email Stock Watch Alerts.
BIGSTRING CORPORATION (OTCBB: BSGC)
Detailed Quote: http://www.otcpicks.com/quotes/BSGC.php
Company Profile: http://www.otcpicks.com/bigstring/bigstring.htm
BigString Corporation, through its subsidiary, BigString Interactive, Inc., provides email services. It offers BigString, which is a Web-based, POP3 server email service solution that allows the user to edit, recall, cancel, and erase the email, as well as insert or delete attachments, even after the email has been sent out and opened. The company also provides BigString Beta 2.0 that offers erasable, recallable, and self destroying applications, non-printable and non-forwardable emails, set time or number of views, and masquerading to protect the sender's privacy and security. BigString Beta 2.0 also provides spam filters, virus protection, and large-storage web-based email accounts. The company's products include BigString Free, which provides the features of BigString Beta 2.0, and includes 1GB of storage and permits the user to send unlimited emails per month; BigString Premium, which offers the features of the BigString Free account, plus vanity domains, POP3 access using any email client, 2GB of storage, and 30 minute video email; and BigString Business that offers the features of the BigString Premium account, plus 10 email accounts, 20GB of storage, global filter notification, and email management. BigString Corporation also offers BigString Marketer Pro, which provides an enterprise marketing software application which allows for the sending of interactive video email commercials that can be programmed to self-destruct at a set time; and BigString Marketer SMB, a hosted video email marketing platform for small and medium size businesses. The company was founded in 2003. It was formerly known as Recall Mail Corporation and changed its name to BigString Corporation in 2005. Bigstring Corporation is based in Red Bank, New Jersey.
BSGC News:
December 18 - BigString Corporation Launches Facebook Application Enabling Users to Send Self-Destructing Videos
BigString Corporation (OTCBB: BSGC) has launched an application for Facebook that enables users to record or upload videos that can be programmed to self-destruct at a specific time or after a set number of views. This is part of a new BigString initiative to develop social networking messaging applications built around the company's core technology.
The video application will allow users to send private self-destructing video messages or to post public video messages to the recipient’s wall. Users can record a video message directly to the application or upload a pre-existing message.
Darin Myman, President and CEO of BigString Corporation, noted that "Video message privacy and security is very important in a world where you can very easily find your personal videos being put up without your permission on sites such as YouTube. Social networks such as Facebook interface well with BigString’s proprietary messaging technology. We provide added value to websites focused on social networking, online dating or user-generated content where protecting a user’s privacy is a major consideration."
RENHUANG PHARMACEUTICALS (OTCBB: RHGP)
Detailed Quote: http://www.otcpicks.com/quotes/RHGP.php
Company Profile: http://www.otcpicks.com/renhuang-pharma/renhuang-pharma.htm
Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang's key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China's natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes. For more information about Renhuang Pharmaceuticals, visit www.renhuang.com.
RHGP News:
December 17 - StockGuru Announces a New Executive Interview With Mr. Li Shaoming of Renhuang Pharmaceuticals
John Pentony, Publisher of Stockguru.com announced that the company has posted a new podcast interview featuring Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP). Pentony interviews Mr. Li Shaoming, CEO and Chairman of the Board, for Renhuang Pharmaceuticals. In the interview Mr. Li discusses the company and its recent news from the company including its recently announced Olympic year prime time television ad space on China Central Television (also known as "CCTV").
To listen to the interview, visit www.stockguru.com/podcasts/?p=21.
EPIX PHARMACEUTICALS (NASD: EPIX)
"Up 46.46% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EPIX.php
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.
EPIX News:
December 18 - EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease; Statistically Significant Improvement in Cognitive Function Achieved Within Two Weeks
EPIX Pharmaceuticals (NASD: EPIX), announced compelling top-line results from a Phase 2a two-week clinical trial of its novel 5-HT4 agonist, PRX-03140, in patients with Alzheimer’s disease. The results show that patients receiving 150 mg of PRX-03140 orally once daily as monotherapy achieved a mean 5.7 point improvement on the Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-cog) versus a 0.2 point worsening in patients on placebo (p= 0.005). Patients on a 50 mg dose of PRX-03140 showed a 1.1 point improvement on the ADAS-cog. The ADAS-cog endpoint is the current standard for evaluating drug efficacy for cognition in Alzheimer’s disease and is an established and accepted registration endpoint.
“The responses observed in this clinical trial over a short duration are promising, and clearly indicate that PRX-03140 is worthy of further study over a longer period and in a larger patient population,” stated Paul Solomon, Ph.D., Professor, Department of Psychology and Program in the Neurosciences, Williams College, and the Clinical Director of the Memory Clinic in Bennington, Vermont. “Our patients are always in need of safe and effective treatments for Alzheimer’s disease, and I am very encouraged by these data.”
After reviewing these data, Serge Gauthier, M.D., Director of the Alzheimer's Disease Research Unit at McGill University, stated, “There is such an urgent and undeniable need for additional safe and effective treatments for Alzheimer’s patients. Findings like these data are not only encouraging and compelling – they appear to represent a step forward in our ability to understand and combat the effects of Alzheimer’s. I look forward to the next clinical trial of PRX-03140 as the development of this drug could be an important advance toward effective Alzheimer’s treatment.”
This Phase 2a clinical trial was a randomized, double-blind, placebo-controlled study to assess the effects of PRX-03140 following two weeks of treatment as monotherapy and separately in combination with donepezil (Aricept®) in patients with mild Alzheimer’s disease. PRX-03140 appeared to be well tolerated alone and in combination with donepezil (Aricept®) with no serious drug-related adverse events. The results show that patients on PRX-03140 alone achieved a statistically significant improvement in ADAS-cog; ADAS-cog changes in the combination arms of the trial were not statistically significant. According to the literature supporting currently approved Alzheimer’s therapies, significant improvements in ADAS-cog measures are not typically observed in less than 12 weeks of therapy.
“We had several responses of note in this trial,” stated Marvin Kalafer, M.D., Principal Investigator at The Clinical Trial Center in Jenkintown, Pennsylvania. “The compelling efficacy and tolerability data observed in this two-week trial are indicative of a profile that would be highly differentiated in the category.”
In pre-clinical models, PRX-03140 has been shown to have a novel mechanism of action that differentiates it from current Alzheimer’s therapies. This oral drug candidate selectively activates the 5-HT4 receptor in the brain. Activation of 5-HT4 not only stimulates the production/release of acetylcholine, which may improve cognitive symptoms of Alzheimer’s, but also stimulates the alpha secretase pathway, potentially slowing disease progression. PRX-03140 has the potential to be the first-in-class 5-HT4 agonist for the treatment of Alzheimer’s disease.
Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX Pharmaceuticals stated, “We are very excited by the measurable impact on memory and cognition, achieved in such a short period of time, in a trial that was designed primarily to assess safety and tolerability. While we recognize that this is a two-week study on a relatively small population of patients, these statistically significant results, as well as the anecdotal reports we have received from study investigators and patients’ families since the trial concluded, support our belief that PRX-03140 has the potential to improve memory and cognition. We look forward to initiating a larger Phase 2b clinical trial early next year to further explore the potential of PRX-03140.”
Trial Design and Results
This Phase 2a clinical trial was conducted across 17 U.S. sites and included 80 patients who were treated for two weeks. Patients were studied on PRX-03140 alone (across three dose arms of 10 patients each: 50 mg once-daily, 150 mg once-daily and placebo) or in a placebo-controlled combination with 10 mg donepezil (Aricept®) (across five dose arms of 10 patients each: PRX-03140 at 5, 25, 50, 100 and 200 mg with donepezil (Aricept )10 mg once-daily). Primary endpoints were safety, tolerability and assessment of quantitative electroencephalograms (qEEG). A battery of cognitive measures, including ADAS-cog assessment, and pharmacokinetic evaluations were measured as secondary endpoints.
Key trial findings include:
Robust and statistically significant improvement in cognitive function as measured by ADAS-cog with PRX-03140 at 150 mg once-daily monotherapy vs. placebo (p=0.005); the rigorous analysis of covariance with the ADAS-cog baseline was used.
This 5.7-point mean improvement in ADAS-cog for the 150 mg dose group compared to a 0.2-point mean worsening on placebo is better than ADAS-cog responses seen in previously published information with approved and experimental agents.
PRX-03140 also showed a statistically significant dose-response for 150 mg vs. 50 mg (monotherapy) vs. placebo (p=0.02).
The onset of benefit of PRX-03140 in Alzheimer’s patients was observed within two weeks.
PRX-03140 produced strong trends in the alteration in brain wave activity (alpha:theta ratio) in the 150 mg dose group versus placebo as measured by qEEG, similar to changes observed with cholinesterase inhibitors.
As monotherapy and in combination with donepezil (Aricept®), PRX-03140 appeared to be well-tolerated with no serious drug-related adverse events.
PRX-03140 is part of EPIX’s worldwide, multi-target strategic collaboration with GlaxoSmithKline to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCR) for the treatment of a variety of diseases, including Alzheimer’s disease. EPIX is responsible for discovery and development of products in the collaboration, including PRX-03140, through to clinical proof of concept, at which point GSK has an exclusive option to license each product for further development and commercialization on a worldwide basis. As part of the collaboration, EPIX received total initial payments of $35 million, including $17.5 million through the purchase of its common stock, and may be eligible to earn up to $1.2 billion in milestones across the four GPCR programs. If GSK exercises the option to license EPIX's PRX-03140 program, EPIX will retain the right to co-promote any products from that program in the United States. Under the collaboration, EPIX is also entitled to receive tiered double-digit royalties of sales by GSK on all collaboration-developed product sales. The alliance is conducted through GSK's Center of Excellence for External Drug Discovery (CEEDD).
About PRX-03140
PRX-03140 is a novel, oral investigational drug candidate for Alzheimer’s disease. It is selective for the 5-HT4 receptor in the brain and is believed to stimulate both acetylcholine production/release – which enables symptomatic improvement in Alzheimer’s patients – and the alpha-secretase pathway – which slows Alzheimer’s disease progression. In three Phase 1 trials and this Phase 2a trial, with more than 180 patients and healthy subjects, PRX-03140 has been well-tolerated. In a 14-day Phase 1b clinical trial, treatment with PRX-03140 resulted in changes in brain wave activity in Alzheimer’s patients that are consistent with those seen in clinical trials with currently approved drugs for Alzheimer’s disease. In preclinical studies, PRX-03140 has shown to improve cognitive function through increasing levels of acetylcholine, soluble amyloid precursor protein (sAPP) and brain-derived neurotrophic factor (BDNF) in regions of the brain known to be important for memory.
PRX-03140 is one of EPIX’s four drug candidates currently in clinical trials discovered through the use of its proprietary computer-based G-Protein Coupled Receptors (GPCR) platform and optimized with integrated computational-medicinal chemistry.
About Alzheimer’s Disease
Alzheimer's disease is a debilitating neurodegenerative disorder characterized by progressive loss of memory and cognitive function, affecting more than 5 million Americans according to the Alzheimer's Association, and more than 9 million worldwide according to the Alzheimer's Disease International Association. The U.S. National Institute of Aging estimates that about 5 percent of the population aged 65-74 and as many as 50 percent of those over age 85 have the disease. Although treatment options are limited, the global market for Alzheimer's disease drugs is growing, from $4 billion in 2006 to over $5 billion expected in 2010, as estimated by Thomson-Pharma.
GREENSHIFT CORPORATION (OTCBB: GSHF)
"Up 114.29% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/GSHF.php
GreenShift Corporation, through its subsidiaries, develops and supports clean technologies and companies that facilitate the use of natural resources. It provides applied engineering and technology transfer services based on clean technology and process innovations. The company also produces ethanol, biodiesel, and other clean fuels from agriproducts. In addition, GreenShift focuses on reducing carbon intensity of energy utilization. Further, it provides transportation and distribution of industrial and hazardous wastes; site remediation and industrial cleaning; engineering and consulting; and environmental, health, and safety compliance services. The company's customers include ethanol facilities; developers of renewable fuel production facilities who purchase its proprietary biodiesel production equipment; industrial manufacturers that purchase its specialty equipment and related manufacturing services; and industrial and governmental clients that generate industrial wastes. GreenShift Corporation is based in New York, New York.
GSHF News:
December 17 - GreenShift Provides Update on Distribution
GreenShift Corporation (OTCBB: GSHF) provided an update to its shareholders regarding the status of its pending distribution.
As previously announced, GreenShift shareholders of record as of December 12, 2007 will receive the following distributions:
This distribution is being made to GreenShift shareholders of record as of December 12, 2007. However, because shares are being distributed, the ex-dividend date for this distribution will be the date on which the certificates are actually mailed to the shareholders.
While the distributions are currently being processed, GreenShift expects to mail the certificates to its shareholders on or about December 26, 2007. The exact mailing date will be announced once all three securities are ready for distribution.
In order to retain the distribution, GreenShift shareholders of record as of December 12, 2007 will need to hold their GreenShift shares until the mailing date.
Any GreenShift shareholder who held shares as of December 12, 2007 but then sells GreenShift shares between December 13, 2007 and the mailing date will be required to deliver the distributed shares to the purchaser when they are received. The delivery of the distributed shares will be accomplished by the seller’s broker.
Likewise, any GreenShift shareholder that purchased GreenShift shares on or after December 13, 2007 and then holds their GreenShift shares until after the mailing date will be entitled to be the final recipient of the distributed shares.
Any questions pertaining to the distribution should be emailed to GreenShift at investorrelations@greenshift.com.
PRIME RESTAURANTS (OTC: PRSU)
"Up 80.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PRSU.php
Prime Restaurants is a start-up restaurant holding company with an eye towards rapid expansion and revenue growth within the next 12 to 24 months. The company will focus only on major well-populated areas such as New York, Connecticut, New Jersey, Florida, Pennsylvania and North and South Carolina with locations that will generate a minimum of $2,000,000 per year at each location.
PRSU News:
December 18 - Prime Restaurants, Inc. Announced Today That It Has Entered Into a Binding Agreement to Acquire Baron International, a Major Restaurant Builder and Equipment Supplier
Prime Restaurants, Inc. (OTC: PRSU) announced that it has entered into a binding agreement to acquire a Major Restaurant Builder and Equipment Supplier.
Prime Restaurants, Inc. is very pleased after several months of negotiations and a lot of give and take on both sides that an agreement could be reached, it is the intent of the company (PRSU) to build a national branded restaurant chain and know that with the experience and knowledge of Baron International and their management team this is within the realm of reality.
Baron International will be a 100% wholly owned subsidiary of PRSU with the original founders and officers of Baron remaining onboard to run the subsidiary. The acquisition is expected to be officially completed by the end of January 2008.
"PRSU is very excited about this acquisition as it will not only bring a very well established and recognized company with significant revenue into the company, but will also enable the company to build its own restaurants at a reduced cost, thus increasing the company's ability to create more of its own locations, reducing build out costs and credibility to our young company," said Mr. Cris Galo President & CEO.
Mr. Galo also stated that, "This is an acquisition that has been pursed for a long time as it will open a whole new world of opportunities for the company, I am delighted that we have finally been able to bring this acquisition to this point."
Mr. Robert Ingala stated, "The merger of these two companies has created a dream come true, while we create a first class operation building restaurants across the country utilizing our expertise and Prime Restaurants' Consumer Base and the Brand Name of PRSU we expect great results."
About Baron International:
Baron International, Inc. was founded in 1982 by Mr. Robert Ingala and Mr. Norman Kushner, since their inception the company has sold beer systems and built many restaurants and systems. Now at this point they have served major companies such as Applebee's, Pepsi, and National Amusement (Mr. Summer Redstone) amongst many other major corporations and others, they are going to move to the next level.
FIRESKY MEDIA CORPORATION (OTC: FSKM)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FSKM.php
Firesky Media Corp., currently based in Irvine, California, is focusing on the electronic hardware and computer component industry. As the Company nears completion of its restructuring activities, the company is in the process of reorganizing its management team and board of directors. The Company plans to change its name during the fourth quarter. More information about Firesky Media can be found at www.fireskymedia.com.
FSKM News:
December 18 - Firesky Signs Letter of Intent to Acquire Sky Electronics, Inc., a Leading OEM Distributor With Annual Revenues of $18.5 Million
Firesky Media Corp. (OTC: FSKM) announced that it has signed a letter of intent to acquire Sky Electronics, Inc. ("Sky") http://www.skyelec.com. Sky's revenue for 2007 will be approximately $18.5 million; they are profitable and have seen sales grow 52% since 2004. Firesky will acquire Sky for $2.5 million in cash and 38% of Firesky common stock.
Sky is a distributor of OEM original products of network gear and server products from the world's leading manufacturers. Through its network of global sources Sky distributes new OEM original packaged products without franchise distribution costs, which provides Sky's customers with access to OEM products at a reduced cost as well as with same day shipping. As a result, Sky has significant margin opportunities and a large customer base.
"Sky has demonstrated its ability to distinguish itself as a nationwide leader in providing its customers with attractive pricing and delivery of innovative technologies in this rapidly growing market segment of OEM packaged products," said John Harris, incoming Firesky President and Chief Executive Officer. "Solution providers are increasingly turning to alternative sources and specialty distributors which is making this market segment extremely attractive. Sky is poised to become a significant leader in this multi-billion market."
"Sky's future is focused on providing our Value Added Reseller customer base with superior pricing, service, and new OEM product solutions," said Dan Rickabus, CEO of Sky. "The acquisition of Sky by Firesky will allow Sky's management team to focus solely on this goal and provide a terrific platform and opportunity to consolidate this fairly fragmented industry segment."
Once the acquisition is complete, Sky will continue to have full autonomy over its day to day operations, with Sky CEO Dan Rickabus joining the Firesky Board of Directors. In addition, Firesky plans to make additional acquisitions of other similar companies. The Company also plans to change its name during the fourth quarter.
About Sky Electronics, Inc.
Sky is a non-franchised stocking distributor of OEM original products. Through its network of global sources and manufacturer's products, Sky provides its customers with new OEM original packaged products without franchise distribution costs, with greater flexibility in policies and procedures, and access to millions of products and same day shipping. Sky is recognized as the low cost distributor of new packaged products, without sacrificing quality, technology or on-time delivery.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover’s Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer:
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:
Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated eight thousand dollars by a third party (StockPromoters.com) for RHGP advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
